DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Ilumya Drug Quantity Management Policy – Per Days
- Ilumya® (tildrakizumab-asmn subcutaneous injection – Sun)

REVIEW DATE: 12/16/2022

OVERVIEW
Ilumya, an interleukin-23 blocker, is indicated for the treatment of adults with moderate to severe **plaque psoriasis** who are candidates for systemic therapy or phototherapy.

Dosing
The recommended dose of Ilumya is 100 mg administered by subcutaneous injection at Weeks 0 and 4 and then once every 12 weeks thereafter.

Availability
Ilumya is available as 100 mg/1 mL single-dose prefilled syringes.

POLICY STATEMENT
This Drug Quantity Management program has been developed to manage potential dose escalation of Ilumya. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail and Home Delivery Maximum Quantity per 84 Days
Ilumya® (tildrakizumab-asmn subcutaneous injection)	100 mg/1 mL prefilled syringe	1 prefilled syringe[α]

[α] This is a quantity sufficient for an 84-day supply at once every 12 week dosing.

CRITERIA
1. If the patient is initiating treatment or requires additional induction dosing, as verified by the absence of claims for Ilumya in the past 130 days, approve a one-time override for 2 prefilled syringes at retail or home delivery.

REFERENCES
1. Ilumya® subcutaneous injection [prescribing information]. Whitehouse Station, NJ: Merck, March 2018.